Armata Pharmaceuticals, Inc. (ARMP)
3.755
0.00 (0.00%)
USD |
NYAM |
Nov 11, 16:00
3.755
0.00 (0.00%)
After-Hours: 20:00
Armata Pharmaceuticals Enterprise Value : 429.30M for Nov. 10, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 10, 2026 | 429.30M |
| November 09, 2026 | 431.15M |
| November 06, 2026 | 420.38M |
| November 05, 2026 | 401.44M |
| November 04, 2026 | 406.64M |
| November 03, 2026 | 404.78M |
| November 02, 2026 | 395.87M |
| October 30, 2026 | 411.84M |
| October 29, 2026 | 410.72M |
| October 28, 2026 | 412.21M |
| October 27, 2026 | 419.64M |
| October 26, 2026 | 418.15M |
| October 23, 2026 | 425.21M |
| October 22, 2026 | 418.15M |
| October 21, 2026 | 403.67M |
| October 20, 2026 | 408.87M |
| October 19, 2026 | 404.04M |
| October 16, 2026 | 415.18M |
| October 15, 2026 | 404.78M |
| October 14, 2026 | 393.27M |
| October 13, 2026 | 405.15M |
| October 12, 2026 | 424.84M |
| October 09, 2026 | 424.84M |
| October 08, 2026 | 433.38M |
| October 07, 2026 | 431.53M |
| Date | Value |
|---|---|
| October 06, 2026 | 433.01M |
| October 05, 2026 | 425.95M |
| October 02, 2026 | 420.75M |
| October 01, 2026 | 412.95M |
| September 30, 2026 | 426.33M |
| September 29, 2026 | 423.35M |
| September 28, 2026 | 430.41M |
| September 25, 2026 | 428.93M |
| September 24, 2026 | 424.47M |
| September 23, 2026 | 425.21M |
| September 22, 2026 | 446.01M |
| September 21, 2026 | 448.24M |
| September 18, 2026 | 445.27M |
| September 17, 2026 | 442.30M |
| September 16, 2026 | 441.18M |
| September 15, 2026 | 453.44M |
| September 14, 2026 | 496.16M |
| September 11, 2026 | 489.84M |
| September 10, 2026 | 484.27M |
| September 09, 2026 | 490.96M |
| September 08, 2026 | 506.19M |
| September 04, 2026 | 506.93M |
| September 03, 2026 | 495.05M |
| September 02, 2026 | 495.42M |
| September 01, 2026 | 486.13M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Lineage Cell Therapeutics, Inc. | 213.38M |
| Voyager Therapeutics, Inc. | 37.17M |
| Black Diamond Therapeutics, Inc. | 5.668M |
| Invivyd, Inc. | 17.62M |
| Elicio Therapeutics, Inc. | 28.67M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 74.14M |
| Revenue (Quarterly) | 2.51M |
| Total Expenses (Quarterly) | -71.63M |
| EPS Diluted (Quarterly) | -0.272 |
| Gross Profit Margin (Quarterly) | 76.45% |
| Earnings Yield | -202.0% |
| Normalized Earnings Yield | -113.23 |